

April 28, 2023

To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
---	--

Subject: Initial Disclosure to be made by an entity identified as a Large Corporate under SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021

Dear Sir/Madam,

Pursuant to Clause 3.1 (a) of Chapter XII of SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 ("SEBI Operational Circular"), please find enclosed herewith the Initial Disclosure in the format as provided in Annexure-XII-A of SEBI Operational Circular for the financial year ended March 31, 2023.

Kindly take the same on your record.

Thanking You,

For **Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

Initial Disclosure to be made by an entity identified as a Large Corporate for the financial year 2023-2024

Sr. No.	Particulars	Details
1.	Name of the Company	Bliss GVS Pharma Limited
2.	CIN	L24230MH1984PLC034771
3.	Outstanding borrowing of the Company as on March 31, 2023 (Rupees in Crores)	Rs. 52.05 Crores
4.	Highest Credit Rating during the previous FY along with the name of the Credit Rating Agency	IVR BBB/ Stable Name of CRA: Infomerics Valuation and Rating Private Limited
5.	Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework	NA

We confirm that we are not a Large Corporate as per the applicability criteria given under Chapter XII of the SEBI Operational circular dated August 10, 2021.

**For and on behalf of the Board of Directors of
Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Deepak Sawant
Chief Financial Officer

Date: April 28, 2023

*In terms of paragraph 2.2(d) of the circular, beginning FY2022, in the event of a shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of the stock exchange to which it would pay the fine in case of a shortfall in the mandatory borrowing through debt markets.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com